Ortec plans US trial for diabetic ulcer treatment
This article was originally published in Clinica
Ortec International looks set to join the race to market a tissue-engineered treatment for diabetic ulcers in the US after submitting an application to the FDA to begin a clinical trial of its Composite Cultured Skin (CCS).
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.